Presentation to highlight new clinical data from COVALENT-111, including c-peptide dataREDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical ...

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic ...

GLP-1 Receptor Agonist Market. The global GLP-1 receptor agonist market is on the verge of unprecedented growth, fueled by ...

Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two other popular classes of diabetes drugs, a U.K. cohort study found. In fully ...

The use of glucagon-like peptide-1 receptor agonists , such as semaglutide—marketed under brand names like Wegovy and Ozempic—has surged among adolescents and young adults. Between 2020 and 2023, the ...

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

Researchers investigating the role of the protein CD44 in obesity and metabolic health found that CD44-deficient mice stayed ...

“The thing most amazing about them is how these drugs suddenly alter the dopamine-related reward pathway in the brain making us less of a slave to cravings. Today, 73% of Americans are obese or ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.